Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure

Inga Hofmann, MD, Daniel Kierstead, Jennie Krasker, Dean Campagna, Klaus Schmitz-Abe, PhD, Kyriacos Markianos, PhD, Michelle A Lee, MD, PhD, Colin A. Sieff, MD, Suneet Agarwal, MD, PHD, Jennifer J Clark, MD, Michael Jeng, MD, Mignon L. Loh, MD, Evan Shereck, MD, David A. Williams, MD, Mark D Fleming, D.Phil., M.D.

Blood (2013) 122 (21): 1520.

https://doi.org/10.1182/blood.V122.21.1520.1520

Published: 2013

Journal Articles

Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin

Elly V. Barry, Jennifer J. Clark, Jan Cools, Johannes Roesel, D. Gary Gilliland

Blood (2007) 110 (13): 4476–4479.

https://doi.org/10.1182/blood-2007-07-101238

Published: 2007

Includes: Supplemental data

Journal Articles

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Blood (2005) 106 (10): 3377–3379.

https://doi.org/10.1182/blood-2005-05-1898

Published: 2005

Journal Articles

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Joseph D. Growney, Jennifer J. Clark, Jennifer Adelsperger, Richard Stone, Doriano Fabbro, James D. Griffin, D. Gary Gilliland

Blood (2005) 106 (2): 721–724.

https://doi.org/10.1182/blood-2004-12-4617

Published: 2005

Journal Articles

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

Jennifer J. Clark, Jan Cools, David P. Curley, Jin-Chen Yu, Nathalie A. Lokker, Neill A. Giese, D. Gary Gilliland

Blood (2004) 104 (9): 2867–2872.

https://doi.org/10.1182/blood-2003-12-4446

Published: 2004

NARROW

GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure

Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

Email alerts

ASH Publications

American Society of Hematology

GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure

Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only